This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

With the validation of the SARS-CoV-2 mRNA vaccines on the global stage, mRNA vaccines and therapeutics are taking the front seat of many biopharma development pipelines. There is an ever-increasing ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created COVID ...

Years from now, when we look back on today’s vaccine development scene, we might say it was almost as consequential as the transition from variolation to vaccination. Variolation, an ancient method, ...

Two scientists who worked on the science behind the COVID-19 vaccine earned the prestigious 2023 Nobel Prize in Physiology or Medicine. Katalin Karikó and Dr. Drew Weissman, both University of ...

Even after a promising experiment sparked expectations for the potential of messenger RNA (mRNA) vaccines, one of the field's early proponents now warns that the treatments have limitations when it ...

PRNewswire/ -- etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one of its key collaborators, Almirall ( ...